Every 10-Q that Ginkgo Bioworks Holdings Inc (DNA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNA filings page.
Ginkgo Bioworks Holdings, Inc. reported Q2 2026 revenue from continuing operations of $20,156 thousand, down sharply from $39,134 thousand a year earlier, mainly due to reduced program scope with a large agriculture customer and fewer projects with pharmaceutical and biotechnology clients. The company still posted a sizable operating loss, with net loss from continuing operations of $57,321 thousand for the quarter and $133,380 thousand for the first half of 2026.
On April 3, 2026, Ginkgo completed the Biosecurity Divestiture, contributing its Biosecurity business to Tower Biosecurity, Inc. (Perimeter) in exchange for equity. This generated a gain on deconsolidation of $24,507 thousand and Q2 income from discontinued operations of $10,611 thousand, partially offsetting continuing losses. Ginkgo now holds an equity method investment in Perimeter of $7,615 thousand and recorded a $4,673 thousand loss on this stake in the first half.
Liquidity remains a key focus. As of June 30, 2026, cash and cash equivalents were $84,535 thousand and marketable securities $217,628 thousand, while net cash used in operating activities totaled $90,959 thousand for the first half. The company also reduced notes receivable to zero fair value, including a senior secured note to Bolt Threads, and raised $16,489 thousand of net proceeds in the first half under its at-the-market equity program, issuing 1.8 million Class A shares.
Ginkgo Bioworks Holdings, Inc. reported another quarterly loss while executing a major portfolio shift in early 2026. For the three months ended March 31, 2026, revenue from continuing operations was $19.5 million, with a net loss from continuing operations of $76.1 million and total net loss of $82.6 million.
The company completed a strategic divestiture of its Biosecurity business: in April 2026 it transferred substantially all Biosecurity operations to Perimeter Systems in exchange for an equity stake representing about 20% of the purchaser on a fully diluted basis. Biosecurity results are now reported as discontinued operations, contributing a further $6.5 million loss in the quarter.
As of March 31, 2026, Ginkgo held $143.9 million in cash and cash equivalents and $229.6 million in marketable securities, with total assets of $1.03 billion and stockholders’ equity of $443.2 million. Operating activities used $46.7 million of cash in the quarter, and a previously unrestricted $47.0 million of cash became restricted in April 2026 to secure a surety bond tied to an automation equipment contract.
Ginkgo Bioworks (DNA) reported a smaller third quarter with a wider loss. Total revenue was $38.8 million, led by Cell Engineering at $29.4 million and Biosecurity at $9.5 million. The company recorded a net loss of $80.8 million and basic EPS of $1.45 loss, reflecting lower revenue and ongoing operating costs.
Liquidity shifted into marketable securities during 2025: cash and cash equivalents were $111.1 million and marketable securities were $350.8 million as of September 30, 2025. Net cash used in operating activities was $123.4 million for the nine months. Stockholders’ equity was $559.8 million.
Ginkgo launched a $100.0 million at‑the‑market program on September 4, 2025 and issued 975,300 Class A shares for $9.4 million in net proceeds. The restructuring begun in 2024 continued, with $10.7 million in year‑to‑date charges and expected workforce reduction costs of $28.0–$30.0 million. An amended Google Cloud agreement reset annual minimums and included a $21.4 million shortfall accrued and a one‑time $14.0 million payment in Q4 2025. As of October 31, 2025, shares outstanding were 48,523,595 Class A, 9,066,624 Class B, and 3,000,000 Class C.
Ginkgo Bioworks (DNA) narrowed its quarterly loss but continues to burn cash. Q2-25 revenue fell 12% YoY to $49.6 M as Biosecurity sales halved to $10.5 M, offset partly by 8% growth in higher-margin Cell Engineering to $39.1 M. Aggressive cost cuts—R&D down 60% to $53.4 M and G&A down 35% to $43.3 M—drove operating loss to $65.5 M versus $222.9 M last year. Net loss improved to $60.3 M (-$1.10 per diluted share) from $217.2 M (-$4.23).
Liquidity shifted from cash to securities. Cash & equivalents dropped 64% to $203.6 M, with $262.6 M deployed into marketable debt securities (now $270.1 M). Operating cash burn was $91.8 M versus $173.6 M a year ago. Total assets declined 11% to $1.23 B; equity fell to $613 M.
Restructuring and future obligations remain key risks. The 2024 restructuring—workforce cut >50% and facility consolidation—added $3.7 M this quarter and is expected to reach up to $29 M. A probable $24 M Google Cloud commitment shortfall looms in Aug-25, and non-refundable DNA supply payments to Twist total $11 M over 2026-27. Deferred revenue slipped 17% since year-end to $102.9 M, hinting at softer pipeline. Shares outstanding after the 1-for-40 reverse split stood at 55.4 M.